In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From PharmaScience

Apotex Loses Moot Appeal On Canadian Zytiga Bar

Apotex fell again in its bid to prove that a key patent in Canada shielding Janssen’s Zytiga (abiraterone acetate) treatment for prostate cancer was obvious. However, the company had already succeeded in obtaining a marketing authorization in a separate action.

Generic Drugs Intellectual Property

Diabetes, Blood-Thinners Dominate Copay Support, But Assistance May Not Be Well Targeted To Need

New comprehensive study of drug coupons offered by manufacturers, pharmacies, pharmacy benefit managers and state programs, and who uses the discounts, takes a more holistic look at patient assistance programs than previous work. Researchers raise concerns that the offsets don’t seem well targeted at people with high financial or clinical need. 

Pricing Debate Private Payers

Two Firms Fight FDA Exclusivity Battles In US

Alvogen contends Teva forfeited 180-day exclusivity with its settlement, while Sandoz claims Sanofi’s MS drug Aubagio isn’t an NCE because it is an active metabolite.

Legal Issues Intellectual Property

US FDA Exclusivity Battles Continue: Alvogen and Sandoz Challenge Buprenorphine, Aubagio Awards

Alvogen contends Teva forfeited 180-day exclusivity with its settlement, while Sandoz claims Sanofi’s MS drug Aubagio isn’t an NCE because it is an active metabolite.

FDA Legal Issues
See All

Company Information

UsernamePublicRestriction

Register